Platelet lysate promotes re-epithelialization of persistent epithelial defects: a pilot study.
Persistent epithelial defects
Platelet lysate
Re-epithelialization
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
23
01
2018
accepted:
16
06
2018
pubmed:
7
7
2018
medline:
7
8
2019
entrez:
7
7
2018
Statut:
ppublish
Résumé
To study the use of autologous platelet lysate prepared in a standardized method for the healing of persistent corneal epithelial defects (PED). Clinical and experimental investigation. In this prospective pilot study (ClinicalTrials.gov identifier NCT02979912), ten patients with a PED duration of a minimum 14 days were included. Autologous platelet lysate was prepared in a standardized methodology. Repeated freeze-thaw cycles were used to lyse the platelets. Patients were advised to apply the eye drops four times a day and were evaluated at baseline and on days 7, 14, 21, 28. No adverse events were reported due to the use of undiluted autologous platelet lysate. A total of 70% of patients had complete re-epithelialization within 28 days. Of these, 40% healed within 14 days (effective group) and 30% within 28 days (partially effective group). Undiluted autologous platelet lysate, prepared according to a standardized methodology, is a safe and effective adjunct therapy for the treatment of PED.
Identifiants
pubmed: 29978342
doi: 10.1007/s10792-018-0968-1
pii: 10.1007/s10792-018-0968-1
doi:
Substances chimiques
Ophthalmic Solutions
0
Banques de données
ClinicalTrials.gov
['NCT02979912']
Types de publication
Journal Article
Langues
eng
Pagination
1483-1490Subventions
Organisme : scientific research support fund (SRF), Ministry of Higher Education/Jordan grant number:.
ID : MPH/1/08/2012
Références
Br J Ophthalmol. 1999 Apr;83(4):390-5
pubmed: 10434857
Ophthalmology. 1999 Oct;106(10):1984-9
pubmed: 10519596
Int Ophthalmol Clin. 2000 Fall;40(4):113-22
pubmed: 11064861
Br J Ophthalmol. 2001 Oct;85(10):1188-97
pubmed: 11567963
Invest Ophthalmol Vis Sci. 2002 Apr;43(4):963-7
pubmed: 11923235
Br J Ophthalmol. 2003 Nov;87(11):1312-6
pubmed: 14609821
Ophthalmology. 2004 Jun;111(6):1115-20
pubmed: 15177961
Eye (Lond). 2004 Jun;18(6):609-14
pubmed: 15184926
Br J Ophthalmol. 2004 Nov;88(11):1467-74
pubmed: 15489495
Ocul Surf. 2007 Jul;5(3):228-39
pubmed: 17660896
Transfusion. 2008 Jun;48(6):1245-55
pubmed: 18410252
Cornea. 2009 Dec;28(10):1104-8
pubmed: 19730088
Brain Res Bull. 2010 Feb 15;81(2-3):229-35
pubmed: 19733636
Eye Contact Lens. 2011 Nov;37(6):370-3
pubmed: 21983552
Arch Ophthalmol. 2011 Dec;129(12):1610-2
pubmed: 22159683
Jpn J Ophthalmol. 2012 Nov;56(6):544-50
pubmed: 22972393
Biomed Res Int. 2013;2013:521315
pubmed: 23984378
Transfus Med Hemother. 2013 Dec;40(6):417-23
pubmed: 24474892
Saudi J Ophthalmol. 2014 Jul;28(3):168-72
pubmed: 25278792
Biomed Res Int. 2016;2016:8406832
pubmed: 27200376
Sci Rep. 2016 Dec 02;6:38143
pubmed: 27909310
PLoS One. 2017 Feb 2;12(2):e0171008
pubmed: 28152010
Arthritis Rheum. 1984 Apr;27(4):459-61
pubmed: 6712760
Graefes Arch Clin Exp Ophthalmol. 1994 Sep;232(9):523-6
pubmed: 7959090